Document is current

Any future updates will be listed below

Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections

Crossref DOI link: https://doi.org/10.1186/s12879-017-2408-7

Published Online: 2017-04-28

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark